Oncology MRI

The MSKai software provides AI-powered segmentation, labeling, and measurement tools for assessment of T2-weighted MRIs of the lumbar spine.

Emerging research suggests that abbreviated breast MRI offers comparable sensitivity and specificity as multiparametric MRI in women with extremely dense breasts with a nearly 50 percent reduction in reading time for radiologists.

New guidelines from the European Society of Urogenital Radiology (ESUR) offer pertinent principles and recommendations for MRI use in considering fertility-sparing treatments for women with ovarian, endometrial, or cervical cancer.

The combination of high-performance gradient technology and AI tools with the Signa Sprint MRI reportedly facilitate enhanced MRI workflow efficiencies in cardiac and oncology imaging.

Catch up on the top radiology content of the past week.

New research findings suggest that image quality and lesion conspicuity are significantly lower with ultrafast breast MRI in comparison to standard dynamic contrast-enhanced breast MRI.

Irrespective of age or O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, gross total resection of IDH wild-type glioblastomas was associated with a median overall survival of 32.6 months, according to new MRI research.

Catch up on the top radiology content of the past week.

Capable of segmenting over 37 organs and structures in the head, neck and pelvis, the MR Contour DL software is currently being showcased at the European Society for Radiotherapy and Oncology (ESTRO) conference.

Catch up on the most well-viewed video interviews from Diagnostic Imaging in April 2025.

Preoperative breast MRI had no impact upon recurrence-free survival and overall survival for women with HER-2 positive, hormone receptor-negative breast cancer, according to a multivariable analysis of a new study involving nearly 1,100 women.

In a recent interview, Wayne Brisbane, M.D., discussed new research, presented at the American Urological Association (AUA) conference, which revealed a 15 percent higher AUC for an emerging AI software in detecting seminal vesicle invasion (SVI) in comparison to prostate MRI alone.

Catch up on the top radiology content of the past week.

An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.

Catch up on the top AI-related news and research in radiology over the past month.

New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.

In a recent interview, Benjamin Kann, M.D., discussed the use of an emerging AI model that can assess longitudinal MR imaging to help predict postoperative recurrence risk for gliomas in pediatric patients.

In a recent interview, Arjun Sahgal, M.D., discussed current and emerging research examining the potential of MRI-guided adaptive radiotherapy for treating glioblastomas.

Catch up on the top radiology content of the past week.

An emerging nomogram model for intra-tumoral heterogeneity quantification with breast MRI demonstrated an average 85 percent sensitivity in external validation testing for predicting pathologic complete response to neoadjuvant chemotherapy for breast cancer.

Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.

Catch up on the top radiology content of the past week.

In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).

A systematic review of 147 clinical trials assessing neoadjuvant systemic therapy for breast cancer also revealed that mid-treatment imaging was utilized in 56 percent of the studies.

Catch up on the top radiology content of the past week.